Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Reasons for hepatotoxic reactions to chemotherapeutic agents and possibilities of their prevention in adolescents with tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001
Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001
Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017 Year: 2018
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017 Year: 2018
Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012
Hepatotoxic reactions in rats after administration of component schemes of reserve Anti-TB drugs with different safety profile Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Pulmonary fibroblasts, an emerging target for bronchodilatory drug Source: Annual Congress 2009 - Translational models of lung disease Year: 2009
Pulmonary complications of infective endocarditis in intravenous drug users Source: Eur Respir J 2001; 18: Suppl. 33, 521s Year: 2001
Lung disease induced by novel chemotherapeutic agents and biomolecules Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006
Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017
Pulmonary onset and complications of intravenous drug users infective endocarditis Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism Year: 2018
Illicit drug use and pulmonary arterial hypertension: Not so frequent Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019
Therapeutic limitations of oral medications to normalize hemodynamics in patients with pulmonary artery hypertension. Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019
Challenging the concept of adding more drugs in pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701527; 10.1183/13993003.01527-2017 Year: 2017
Anti-inflammatory therapies in bronchiectasis Source: Eur Respir Mon 2011; 52: 223-238 Year: 2011
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013